ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Halime
|
1.3K |
543K |
1 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.3K
|
543K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Halime
|
1.3K |
543K |
1 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.3K
|
543K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Halime
|
3.4K |
1.1M |
0 |
21/06/23 |
21/06/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
Halime
|
1.0K |
382K |
5 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
1.0K
|
382K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
Halime
|
1.0K |
382K |
1 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
382K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
Halime
|
42 |
17K |
1 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
42
|
17K
|
1
|
|
ASX - By Stock
|
MNS |
Re:
How much MNS worth without Tesla deal
|
|
Halime
|
38 |
20K |
4 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
38
|
20K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
Halime
|
42 |
17K |
0 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
42
|
17K
|
0
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
Halime
|
42 |
17K |
4 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
42
|
17K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
Halime
|
42 |
17K |
5 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
42
|
17K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
Halime
|
42 |
17K |
1 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
42
|
17K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Ann: CUV Appendix 4D Half Year Report
|
|
Halime
|
42 |
17K |
1 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
42
|
17K
|
1
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Global SCENESSE demand drives increased revenues, earnings
|
|
Halime
|
1 |
813 |
2 |
24/02/23 |
24/02/23 |
ASX - By Stock
|
1
|
813
|
2
|
|
ASX - By Stock
|
MNS |
Re:
Ann: Magnis Signs Offtake Agreement
|
|
Halime
|
254 |
119K |
5 |
22/02/23 |
22/02/23 |
ASX - By Stock
|
254
|
119K
|
5
|
|
ASX - By Stock
|
MNS |
Re:
Ann: Magnis Signs Offtake Agreement
|
|
Halime
|
254 |
119K |
4 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
254
|
119K
|
4
|
|
ASX - By Stock
|
MNS |
Re:
Ann: Magnis Signs Offtake Agreement
|
|
Halime
|
254 |
119K |
2 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
254
|
119K
|
2
|
|
ASX - By Stock
|
CUV |
Re:
Cash Flows are deceiving
|
|
Halime
|
7 |
4.0K |
3 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
7
|
4.0K
|
3
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Halime
|
32 |
12K |
5 |
02/02/23 |
02/02/23 |
ASX - By Stock
|
32
|
12K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
|
|
Halime
|
914 |
285K |
5 |
01/02/23 |
01/02/23 |
ASX - By Stock
|
914
|
285K
|
5
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Halime
|
32 |
12K |
4 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
32
|
12K
|
4
|
|
ASX - By Stock
|
CUV |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Halime
|
32 |
12K |
0 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
32
|
12K
|
0
|
|
ASX - By Stock
|
SYR |
Re:
Media Reports
|
|
Halime
|
3.5K |
1.3M |
0 |
30/01/23 |
30/01/23 |
ASX - By Stock
|
3.5K
|
1.3M
|
0
|
|
ASX - By Stock
|
CUV |
Re:
CUV Charting
|
|
Halime
|
131 |
66K |
0 |
27/01/23 |
27/01/23 |
ASX - By Stock
|
131
|
66K
|
0
|
|
ASX - By Stock
|
CUV |
Re:
CUV Charting
|
|
Halime
|
131 |
66K |
2 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
131
|
66K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Halime
|
1.0K |
270K |
4 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
1.0K
|
270K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Halime
|
1.0K |
270K |
3 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
1.0K
|
270K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
|
|
Halime
|
1.0K |
270K |
4 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
1.0K
|
270K
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
0 |
17/08/21 |
17/08/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C Quarterly Activity Report
|
|
Halime
|
281 |
76K |
2 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
281
|
76K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Halime
|
5.0K |
2.4M |
2 |
21/07/21 |
21/07/21 |
ASX - By Stock
|
5.0K
|
2.4M
|
2
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
3 |
15/07/21 |
15/07/21 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
3 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
1 |
02/07/21 |
02/07/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
4 |
02/07/21 |
02/07/21 |
ASX - By Stock
|
10K
|
3.0M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Halime
|
1.5K |
411K |
1 |
26/06/21 |
26/06/21 |
ASX - By Stock
|
1.5K
|
411K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
$90 a share on COVID ARDS Authorization ?
|
|
Halime
|
260 |
80K |
2 |
25/06/21 |
25/06/21 |
ASX - By Stock
|
260
|
80K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Where is Novartis?
|
|
Halime
|
1.5K |
411K |
1 |
24/06/21 |
24/06/21 |
ASX - By Stock
|
1.5K
|
411K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
3 |
18/06/21 |
18/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Third member of FDA advisory panel resigns
|
|
Halime
|
98 |
36K |
1 |
14/06/21 |
14/06/21 |
ASX - By Stock
|
98
|
36K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
0 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
1 |
11/06/21 |
11/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
5 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2021.... Year of the boom ?
|
|
Halime
|
346 |
109K |
1 |
07/06/21 |
07/06/21 |
ASX - By Stock
|
346
|
109K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
2021.... Year of the boom ?
|
|
Halime
|
346 |
109K |
2 |
07/06/21 |
07/06/21 |
ASX - By Stock
|
346
|
109K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
2021.... Year of the boom ?
|
|
Halime
|
346 |
109K |
3 |
07/06/21 |
07/06/21 |
ASX - By Stock
|
346
|
109K
|
3
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
1 |
07/06/21 |
07/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
0 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
0 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
0 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading 2021 - paradigm shift
|
|
Halime
|
10K |
3.0M |
0 |
28/05/21 |
28/05/21 |
ASX - By Stock
|
10K
|
3.0M
|
0
|
|